v3.21.1
Collaborations (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Collaborative and license agreements      
AbbVie's receivable from Janssen $ 9,588   $ 8,822
AbbVie's payable to Janssen 20,604   20,159
Janssen Biotech Inc. | Collaborative arrangement      
Collaborative and license agreements      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 70 $ 70  
AbbVie's receivable from Janssen 309   283
AbbVie's payable to Janssen 460   $ 562
Janssen Biotech Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 465 450  
Janssen Biotech Inc. | Collaborative arrangement | International      
Collaborative and license agreements      
International - AbbVie's share of profits (included in net revenues) 269 266  
Genentech, Inc. | Collaborative arrangement      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 159 128  
AbbVie's share of development costs (included in R&D) 42 25  
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 11 $ 14